Oculis Holding AG (Nasdaq: $OCS): PREDICT-1 Starts as Licaminlimab Becomes the Next Test After the DIAMOND Phase 3 Miss

The headline: PREDICT-1 is now live in patients

Oculis announced on June 9, 2026 that the first patient has been randomized in PREDICT-1, the genotype-based registrational trial of Licaminlimab in dry eye disease. The company describes PREDICT-1 as the first genotype-based registrational trial in dry eye disease and frames Licaminlimab as a potential first-in-class precision medicine approach for the condition.

The trial is designed to evaluate the efficacy and safety of Licaminlimab compared with vehicle in patients carrying a specific TNFR1 genotype, while also evaluating the effect in the overall study population. The planned enrollment is approximately 160 patients, with roughly two-thirds expected to carry the specified TNFR1 genotype. The primary endpoint is the change from baseline to Day 29 in global ocular discomfort severity score in the genotype-defined group; the same outcome measure will be evaluated in the overall population as a key secondary endpoint.

That design is important because dry eye disease has historically been a frustrating market for patients, clinicians and companies. Symptoms are subjective, response heterogeneity is common, and the commercial landscape has often relied on broad-label anti-inflammatory approaches rather than true precision selection. Oculis is trying to change the question from “does this help the average dry eye population?” to “can a biologically defined subgroup show a cleaner, stronger response?”

Why this matters after the DIAMOND miss

This update needs to be read in the right context. Before the DIAMOND readout, Oculis still had a major near-term thesis around OCS-01 as a potential non-invasive topical treatment for diabetic macular edema. That thesis was reset on May 29, 2026, when the company announced that both DIAMOND Phase 3 trials failed to meet the primary endpoint of mean change in best corrected visual acuity at Week 52. The key secondary endpoint of at least a 15-letter BCVA gain was also not met in both trials.

The DIAMOND data were not biologically empty. Oculis reported a substantial and persistent retinal thickness reduction by OCT, and the safety profile was described as consistent with previous trials. But the problem for a DME registration story is straightforward: the visual endpoints did not support a clean filing path. Oculis said that, based on the results, it does not currently plan to pursue an FDA regulatory filing for OCS-01 in DME.

That is why PREDICT-1 matters. It gives the company a fresh late-stage execution point after the DME reset. The market no longer needs to debate whether DIAMOND was a clean win. It was not. The question now is whether Oculis can use its cash position and remaining pipeline to generate the next credible catalyst arc through Licaminlimab and Privosegtor.

The real test: can genotype selection reduce dry eye trial noise?

Oculis’ thesis for Licaminlimab is based on a precision-medicine approach in a disease that has not historically been treated that way. In prior Phase 2 studies, the company reported that Licaminlimab showed a substantially greater treatment effect in patients carrying a specific TNFR1 genotype, with effects described as ranging from five-fold greater in signs to seven-fold greater in symptoms. PREDICT-1 is designed to leverage those findings.

The logic is attractive. If a subgroup is more likely to respond, selecting for that subgroup could improve trial efficiency, strengthen the effect size and create a more differentiated label. It could also help explain why broad dry eye populations are difficult: dry eye disease is multifactorial, and not every patient’s inflammatory biology is the same.

But this is also where the risk sits. A genotype-enriched trial can sharpen the signal only if the biomarker is real, reproducible and clinically meaningful. If the subgroup does not perform as expected, the precision-medicine narrative weakens quickly. If the subgroup performs well but the overall population is weak, investors will need to think carefully about addressable market, testing logistics, adoption, payer logic and how clinicians would identify the right patients.

What PREDICT-1 is actually measuring

What does not change

The PREDICT-1 start does not undo the DIAMOND result. OCS-01 in DME is no longer the clean near-term filing story it was before May 29. The correct framework is now a pipeline reset: Oculis still has cash, clinical assets and future catalysts, but the equity story has moved away from a near-term DME approval run-up and toward Licaminlimab, Privosegtor and execution after the Phase 3 miss.

It also does not make Licaminlimab a proven commercial asset. First patient randomized is an execution milestone, not an efficacy readout. The dry eye disease market is large, but large markets do not automatically translate into clean uptake. Current disease management is described by Oculis as trial-and-error, with only a minority of patients experiencing sustained relief and high discontinuation rates in the first six months. That creates opportunity, but it also shows why the category is hard.

The strongest version of the OCS story now depends on sequencing. The company needs PREDICT-1 execution, a credible readout, continued Privosegtor progress, disciplined resource allocation after DIAMOND, and no major erosion of the cash runway. The company’s $277.6 million cash, equivalents and short-term investments at March 31, 2026 and runway guidance into the second half of 2029 are important because they give Oculis time to work through that sequence without immediate survival pressure.

How this changes the catalyst map

The catalyst map has become cleaner after the DIAMOND miss, even if the equity story became less attractive in the short term. Before DIAMOND, investors had one very visible DME event that could define the stock. After DIAMOND, the market has to follow a broader late-stage pipeline sequence.

Licaminlimab now becomes one of the main near-term proof points. A strong PREDICT-1 result would help show that Oculis still has productive late-stage development capacity after the OCS-01 setback. A weak result would be more damaging because it would shift even more of the story onto Privosegtor and reduce confidence in management’s ability to convert late-stage ophthalmology programs into value.

Privosegtor remains the other major pillar. Oculis has highlighted FDA Breakthrough Therapy designation in optic neuritis, EMA PRIME designation and an FDA Special Protocol Assessment agreement for the PIONEER-1 registrational trial. That program is now central to the medium-term rebuild, especially because it targets optic neuropathies with meaningful unmet need.

Trading and market setup

For traders, the update is probably best read as a narrative stabilization event rather than a full rerating trigger by itself. The stock had already absorbed the DIAMOND disappointment; today’s news gives the market a reason to refocus on the pipeline that remains. That can matter in a small/mid-cap biotech tape, especially when the company is funded and the next catalyst is now formally underway.

The risk is that first-patient news can be overplayed. It is not data. It is not an approval event. It does not prove the genotype strategy works. The clean trading question is whether the market begins to rebuild interest ahead of the PREDICT-1 readout window, not whether today’s milestone alone changes the entire valuation.

The most useful framework is simple: Oculis is no longer a DIAMOND/DME filing setup. It is a funded ophthalmology pipeline reset with two main pillars to watch — Licaminlimab in dry eye disease and Privosegtor in optic neuropathies. PREDICT-1 starting patient randomization is the first meaningful step in proving that the reset has a real next chapter.

Bottom line

Oculis’ June 9 update is constructive because it moves Licaminlimab from “planned late-stage catalyst” to an actively randomized registrational program. That matters after the DIAMOND miss because the company needs a new proof point capable of rebuilding investor confidence.

The update should not be sold as a cure for the DME disappointment. It is not. DIAMOND reset the OCS story, and OCS-01 in diabetic macular edema is no longer the central near-term regulatory driver. But PREDICT-1 gives Oculis a credible new catalyst path, especially because the trial is genotype-based, relatively focused and designed around a differentiated precision-medicine thesis in dry eye disease.

The next serious question is not whether the trial has started. It has. The question is whether genotype selection can produce a strong enough clinical signal to matter in a dry eye market that badly needs better targeting but has historically punished weak, noisy or poorly differentiated approaches.